213 related articles for article (PubMed ID: 29871612)
1. Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma.
Peraldo-Neia C; Ostano P; Cavalloni G; Pignochino Y; Sangiolo D; De Cecco L; Marchesi E; Ribero D; Scarpa A; De Rose AM; Giuliani A; Calise F; Raggi C; Invernizzi P; Aglietta M; Chiorino G; Leone F
BMC Genomics; 2018 Jun; 19(1):440. PubMed ID: 29871612
[TBL] [Abstract][Full Text] [Related]
2. Intrahepatic cholangiocarcinomas with IDH1/2 mutation-associated hypermethylation at selective genes and their clinicopathological features.
Lee K; Song YS; Shin Y; Wen X; Kim Y; Cho NY; Bae JM; Kang GH
Sci Rep; 2020 Sep; 10(1):15820. PubMed ID: 32978444
[TBL] [Abstract][Full Text] [Related]
3. IDH1 as a frequently mutated gene has potential effect on exosomes releasement by epigenetically regulating P2RX7 in intrahepatic cholangiocarcinoma.
Zhang X; Miao R; Liu T; Xiang X; Gu J; Jia Y; Li Z; Fu Y; He Y; Zhang Y; Zhang J; Qu K; Liu C
Biomed Pharmacother; 2019 May; 113():108774. PubMed ID: 30889491
[TBL] [Abstract][Full Text] [Related]
4. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
Goyal L; Govindan A; Sheth RA; Nardi V; Blaszkowsky LS; Faris JE; Clark JW; Ryan DP; Kwak EL; Allen JN; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Chong DQ; Deshpande V; Borger DR; Iafrate AJ; Bardeesy N; Zheng H; Zhu AX
Oncologist; 2015 Sep; 20(9):1019-27. PubMed ID: 26245674
[TBL] [Abstract][Full Text] [Related]
5. Mutation of
Su L; Zhang X; Zheng L; Wang M; Zhu Z; Li P
Front Endocrinol (Lausanne); 2020; 11():189. PubMed ID: 32373065
[No Abstract] [Full Text] [Related]
6. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
Borger DR; Goyal L; Yau T; Poon RT; Ancukiewicz M; Deshpande V; Christiani DC; Liebman HM; Yang H; Kim H; Yen K; Faris JE; Iafrate AJ; Kwak EL; Clark JW; Allen JN; Blaszkowsky LS; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Bardeesy N; Straley KS; Agresta S; Schenkein DP; Ellisen LW; Ryan DP; Zhu AX
Clin Cancer Res; 2014 Apr; 20(7):1884-90. PubMed ID: 24478380
[TBL] [Abstract][Full Text] [Related]
7. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.
Ma B; Meng H; Tian Y; Wang Y; Song T; Zhang T; Wu Q; Cui Y; Li H; Zhang W; Li Q
BMC Cancer; 2020 Apr; 20(1):318. PubMed ID: 32293336
[TBL] [Abstract][Full Text] [Related]
8. Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma.
Wang T; Drill E; Vakiani E; Pak LM; Boerner T; Askan G; Schvartzman JM; Simpson AL; Jarnagin WR; Sigel CS
Hum Pathol; 2019 Sep; 91():19-25. PubMed ID: 31121195
[TBL] [Abstract][Full Text] [Related]
9. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
[TBL] [Abstract][Full Text] [Related]
10. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1.
Fujiwara H; Tateishi K; Kato H; Nakatsuka T; Yamamoto K; Tanaka Y; Ijichi H; Takahara N; Mizuno S; Kogure H; Matsubara S; Nakai Y; Koike K
Cancer Sci; 2018 Nov; 109(11):3602-3610. PubMed ID: 30156013
[TBL] [Abstract][Full Text] [Related]
12. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.
Zhu AX; Borger DR; Kim Y; Cosgrove D; Ejaz A; Alexandrescu S; Groeschl RT; Deshpande V; Lindberg JM; Ferrone C; Sempoux C; Yau T; Poon R; Popescu I; Bauer TW; Gamblin TC; Gigot JF; Anders RA; Pawlik TM
Ann Surg Oncol; 2014 Nov; 21(12):3827-34. PubMed ID: 24889489
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry using monoclonal antibody MsMab-2 is useful to detect IDH1 R132L in intrahepatic cholangiocarcinoma.
Hayashi A; Misumi K; Shibahara J; Kokudo N; Kato Y; Fukayama M
Pathol Int; 2016 Oct; 66(10):578-582. PubMed ID: 27595804
[TBL] [Abstract][Full Text] [Related]
14. Mutational landscape of intrahepatic cholangiocarcinoma.
Zou S; Li J; Zhou H; Frech C; Jiang X; Chu JS; Zhao X; Li Y; Li Q; Wang H; Hu J; Kong G; Wu M; Ding C; Chen N; Hu H
Nat Commun; 2014 Dec; 5():5696. PubMed ID: 25526346
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Immunogenomic Profiling of
Makawita S; Lee S; Kong E; Kwong LN; Abouelfetouh Z; Danner De Armas A; Xiao L; Murugesan K; Danziger N; Pavlick D; Korkut A; Ross JS; Javle M
JCO Precis Oncol; 2024 Mar; 8():e2300544. PubMed ID: 38547421
[TBL] [Abstract][Full Text] [Related]
16. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.
Grassian AR; Pagliarini R; Chiang DY
Curr Opin Gastroenterol; 2014 May; 30(3):295-302. PubMed ID: 24569570
[TBL] [Abstract][Full Text] [Related]
17. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
[TBL] [Abstract][Full Text] [Related]
18. Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study.
Niger M; Nichetti F; Casadei-Gardini A; Rizzato MD; Pircher C; Bini M; Franza A; Rimini M; Burgio V; Sposetti C; Fornaro L; Rapposelli IG; D'Amico FE; Aprile G; Vivaldi C; Frassineti GL; Milione M; Leoncini G; Cappetta A; Vasile E; Fassan M; Morano F; Perrone F; Tamborini E; Pruneri G; Lonardi S; Mazzaferro V; Pietrantonio F; Di Bartolomeo M; de Braud F
Int J Cancer; 2022 Oct; 151(8):1310-1320. PubMed ID: 35723131
[TBL] [Abstract][Full Text] [Related]
19. Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center.
Kinzler MN; Jeroch J; Klasen C; Himmelsbach V; Koch C; Finkelmeier F; Trojan J; Zeuzem S; Pession U; Reis H; Demes MC; Wild PJ; Walter D
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6391-6398. PubMed ID: 36757619
[TBL] [Abstract][Full Text] [Related]
20. Platinum Sensitivity in
Doroshow DB; Wei W; Mehrotra M; Sia D; Eder JP; Bindra R; Houldsworth J; LoRusso P; Walther Z
Cancer Invest; 2023 Sep; 41(7):646-655. PubMed ID: 37505929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]